171094-50-1

171094-50-1 structure

Name: ZANAMIVIR HYDRATE
Chemical Name: ZANAMIVIR HYDRATE
CAS Number: 171094-50-1
Molecular Formula: C₁₂H₂₂N₄O₈
Molecular Weight: 350.325
Catalog: Signaling Pathways Anti-infection Influenza Virus
Create Date: 2021-09-10 18:29:52
Modify Date: 2025-08-25 14:40:11
Zanamivir hydrate (5:1) is the hydrate of Zanamivir. Zanamivir is an influenza viral neuraminidase inhibitor with IC50 values of 0.95 nM and 2.7 nM for influenza A and B, respectively[1].

Name	ZANAMIVIR HYDRATE
Synonyms	D-glycero-D-galacto-Non-2-enonic acid, 5-(acetylamino)-4-[(aminoiminomethyl)amino]-2,6-anhydro-3,4,5-trideoxy-, hydrate (1:1) ZANAMIVIR HYDRATE D-glycero-D-galacto-Non-2-enonic acid, 5-(acetylamino)-4-[(aminoiminomethyl)amino]-2,6-anhydro-3,4,5-trideoxy-, hydrate (5:1) MFCD03791324 (6R)-5-Acetamido-2,6-anhydro-4-carbamimidamido-3,4,5-trideoxy-6-[(1R,2R)-1,2,3-trihydroxypropyl]-L-threo-hex-2-enonic acid hydrate (1:1)

Description	Zanamivir hydrate (5:1) is the hydrate of Zanamivir. Zanamivir is an influenza viral neuraminidase inhibitor with IC50 values of 0.95 nM and 2.7 nM for influenza A and B, respectively[1].
Related Catalog	Signaling Pathways >> Anti-infection >> Influenza Virus Research Areas >> Infection
Target	IC50: 0.95 nM (Influenza A); 2.7 nM (Influenza B)[1]
In Vivo	Zanamivir has a poor bioavailability in oral administration, with only 4–17% of the agent. Oral delivery of Zanamivir has been a problem due to its strong hydrophilic nature that limits its transport across the intestinal epithelium. Permeation enhancers such as sodium cholate, hydroxypropyl β-cyclodextrin could be used with zanamivir to enhance the intestinal permeability[3].
References	[1]. Gubareva LV, et al. Comparison of the activities of zanamivir, oseltamivir, and RWJ-270201 against clinical isolates ofinfluenza virus and neuraminidase inhibitor-resistant variants. Antimicrob Agents Chemother. 2001 Dec;45(12):3403-8. [2]. McKimm-Breschkin JL, et al. Management of influenza virus infections with neuraminidase inhibitors: detection, incidence, and implications of drug resistance. Treat Respir Med. 2005;4(2):107-16. [3]. Shanmugam S, et al. Zanamivir oral delivery: enhanced plasma and lung bioavailability in rats. Biomol Ther (Seoul). 2013 Mar;21(2):161-9.